Paris-based Aqemia expands globally with fresh investment
Paris-based Aqemia’s AI platform bypasses experimental data, accelerating cancer and immuno-oncology drug development.
Aqemia has secured $38 million in funding led by Cathay Innovation, marking its second successful raise this year and bringing its total funding past $100 million. Founded in 2019, the company leverages a unique combination of ‘quantum-inspired’ physics and generative AI to accelerate drug discovery, focusing initially on cancer and immuno-oncology treatments.
By using statistical mechanics algorithms, Aqemia creates synthetic data to predict drug molecule properties, bypassing the costly need for experimental data. The France-based startup’s approach has already attracted partnerships, including a lucrative agreement with Sanofi worth up to $140 million.
The latest funding will support Aqemia’s global expansion, with a London office set to open in 2025, tapping into the UK‘s talent pool. Backers include Cathay Innovation and previous investors such as Bpifrance and Eurazeo, boosting the company’s reach into international markets.
About author
DW Team
The GIP Digital Watch Observatory team, consisting of over 30 digital policy experts from around the world, excels in the fields of research and analysis on digital policy issues. The team is backed by the creative prowess of Creative Lab Diplo and the technical expertise of the Diplo tech team.
